ESMO-EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent/metastatic disease

被引：17
作者：
Bossi, P. [1 ]
Chan, A. T. [2 ]
Even, C. [3 ]
Machiels, J. -P. [4 ,5 ]
机构：
[1] Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Med Oncol, ASST Spedali Civili, Brescia, Italy
[2] Chinese Univ Hong Kong, State Key Lab Translat Oncol, Shatin, Hong Kong, Peoples R China
[3] Gustave Roussy, Head & Neck Dept, Paris, France
[4] Clin Univ St Luc, Inst Roi Albert II, Serv Oncol Med, Brussels, Belgium
[5] Catholic Univ Louvain, Inst Rech Clin & Expt POLE MIRO, Brussels, Belgium
[6] ESMO Guidelines Comm, ESMO Head Off, Via Ginevra 4, CH-6900 Lugano, Switzerland
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷 / 03期
关键词：
nasopharyngeal carcinoma; Clinical Practice Guideline; capecitabine; adjuvant; immunotherapy; recurrent and/or metastatic;
D O I：
10.1016/j.annonc.2022.11.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：247 / 250
页数：4
相关论文
共 6 条
  • [1] Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Bossi, P.
    Chan, A. T.
    Licitra, L.
    Trama, A.
    Orlandi, E.
    Hui, E. P.
    Halamkova, J.
    Mattheis, S.
    Baujat, B.
    Hardillo, J.
    Smeele, L.
    van Herpen, C.
    Castro, A.
    Machiels, J-P
    [J]. ANNALS OF ONCOLOGY, 2021, 32 (04) : 452 - 465
  • [2] Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
    Chen, Yu-Pei
    Liu, Xu
    Zhou, Qin
    Yang, Kun-Yu
    Jin, Feng
    Zhu, Xiao-Dong
    Shi, Mei
    Hu, Guo-Qing
    Hu, Wei-Han
    Sun, Yan
    Wu, Hong-Fen
    Wu, Hui
    Lin, Qin
    Wang, Hui
    Tian, Ye
    Zhang, Ning
    Wang, Xi-Cheng
    Shen, Liang-Fang
    Liu, Zheng-Zheng
    Huang, Jing
    Luo, Xiu-Ling
    Li, Ling
    Zang, Jian
    Mei, Qi
    Zheng, Bao-Min
    Yue, Dan
    Xu, Jing
    Wu, San-Gang
    Shi, Yan-Xia
    Mao, Yan-Ping
    Chen, Lei
    Li, Wen-Fei
    Zhou, Guan-Qun
    Sun, Rui
    Guo, Rui
    Zhang, Yuan
    Xu, Cheng
    Lv, Jia-Wei
    Guo, Ying
    Feng, Hui-Xia
    Tang, Ling-Long
    Xie, Fang-Yun
    Sun, Ying
    Ma, Jun
    [J]. LANCET, 2021, 398 (10297) : 303 - 313
  • [3] ESMO-Magnitude of Clinical Benefit Scale version 1.1
    Cherny, N. I.
    Dafni, U.
    Bogaerts, J.
    Latino, N. J.
    Pentheroudakis, G.
    Douillard, J. -Y.
    Tabernero, J.
    Zielinski, C.
    Piccart, M. J.
    de Vries, E. G. E.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (10) : 2340 - 2366
  • [4] Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
    Mai, Hai-Qiang
    Chen, Qiu-Yan
    Chen, Dongping
    Hu, Chaosu
    Yang, Kunyu
    Wen, Jiyu
    Li, Jingao
    Shi, Ying-Rui
    Jin, Feng
    Xu, Ruilian
    Pan, Jianji
    Qu, Shenhong
    Li, Ping
    Hu, Chunhong
    Liu, Yi-Chun
    Jiang, Yi
    He, Xia
    Wang, Hung-Ming
    Lim, Wan-Teck
    Liao, Wangjun
    He, Xiaohui
    Chen, Xiaozhong
    Liu, Zhigang
    Yuan, Xianglin
    Li, Qi
    Lin, Xiaoyan
    Jing, Shanghua
    Chen, Yanju
    Lu, Yin
    Hsieh, Ching-Yun
    Yang, Muh-Hwa
    Yen, Chia-Jui
    Samol, Jens
    Feng, Hui
    Yao, Sheng
    Keegan, Patricia
    Xu, Rui-Hua
    [J]. NATURE MEDICINE, 2021, 27 (09) : 1536 - +
  • [5] Miao J, 2022, JAMA ONCOL
  • [6] Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
    Yang, Yunpeng
    Qu, Song
    Li, Jingao
    Hu, Chaosu
    Xu, Mingjun
    Li, Weidong
    Zhou, Ting
    Shen, Liangfang
    Wu, Hui
    Lang, Jinyi
    Hu, Guangyuan
    Luo, Zhanxiong
    Fu, Zhichao
    Qu, Shenhong
    Feng, Weineng
    Chen, Xiaozhong
    Lin, Shaojun
    Zhang, Weimin
    Li, Xiaojiang
    Sun, Yan
    Lin, Zhixiong
    Lin, Qin
    Lei, Feng
    Long, Jianting
    Hong, Jinsheng
    Huang, Xiaoming
    Zeng, Lingzhi
    Wang, Peiguo
    He, Xiaohui
    Zhang, Ben
    Yang, Qing
    Zhang, Xiaojing
    Zou, Jianjun
    Fang, Wenfeng
    Zhang, Li
    [J]. LANCET ONCOLOGY, 2021, 22 (08) : 1162 - 1174
1